Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amitifadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 15/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 15/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 15/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amitifadine SCHEMBL30231901 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL378242 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL2855350 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL2855353 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL378061 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL8213058 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL12313135 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL9604846 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL29393526 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL4552778 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 825 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. (US) | 2024-12-12 | — | — | US | claimed |
| EP-4395772-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | Ethismos Research, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| CN-118176001-A | Methods for preventing and treating pain and related symptoms | 埃塞斯莫斯研究股份有限公司 | 2024-06-11 | — | — | CN | claimed |
| US-20230085440-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | ETHISMOS RESEARCH, INC. (US) | 2023-03-16 | — | — | US | claimed |
| WO-2023034293-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | ETHISMOS RESEARCH, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| US-20210161863-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | MCKINNEY ANTHONY ALEXANDER (US) | 2021-06-03 | — | — | US | claimed |
| US-20210046044-A1 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | MCKINNEY ANTHONY ALEXANDER (US) | 2021-02-18 | — | — | US | claimed |
| US-20210047268-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMISTTERS | ETHISMOS RESEARCH, INC. | 2021-02-18 | — | — | US | claimed |
| US-20180296527-A1 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | ETHISMOS RESEARCH, INC. | 2018-10-18 | — | — | US | claimed |
| US-20180256542-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. | 2018-09-13 | — | — | US | claimed |
| US-20040157870-A1 | (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor | LIPPA ARNOLD STAN (US) | 2004-08-12 | — | — | US | claimed |
| US-20040132797-A1 | (+)-1-(3,4-dichlorrophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof | ETHISMOS RESEARCH, INC. | 2004-07-08 | — | — | US | claimed |
| US-6716868-B2 | ATTENTION DEFICIT DISORDER, DEPRESSION, OBESITY, PARKINSON'S DISEASE, A TIC DISORDER, AN ADDICTIVE DISORDER; FREE OF THE CORRESPONDING (+) ENANTIOMER TO ALLEVIATE SIDE EFFECTS | DOV PHARMACEUTICAL INC | 2004-04-06 | — | — | US | claimed |
| EP-1349835-A2 | (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO 3.1.0]HEXANE, COMPOSITIONS AND USES THEREOF | DOV Pharmaceutical Inc. (US) | 2003-10-08 | — | — | EP | claimed |
| US-20030181508-A1 | (-)-1-(3,4-DichlorophenyI)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor | DOV PHARMACEUTICALS, INC. | 2003-09-25 | — | — | US | claimed |
| US-6569887-B2 | For treating attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder | DOV PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | claimed |
| US-20030045567-A1 | (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor | DOV PHARMACEUTICAL, INC. | 2003-03-06 | — | — | US | claimed |
| WO-2002066427-A2 | (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE, COMPOSITIONS AND USES THEREOF | DOV PHARMACEUTICAL, INC. (US) | 2002-08-29 | — | — | WO | claimed |
| US-6372919-B1 | SUBSTANTIALLY FREE OF CORRESPONDING (-)-ENANTIOMER | DOV PHARMACEUTICAL, INC. | 2002-04-16 | — | — | US | claimed |
| US-6204284-B1 | ALCOHOL OR COCAINE ABUSE | AMERICAN CYANAMID COMPANY | 2001-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047268-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMISTTERS | SLC18A2, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 3/4885 |
| US-20210046044-A1 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | ADH1C, ADH1A, ADH5 | SLC6A2 28/4885SLC6A4 37/4885SLC6A3 4/4885 |
| US-20230085440-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | KCNN3, KCNN2, KCNN1 | SLC6A2 71/4885SLC6A4 43/4885SLC6A3 103/4885 |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 4/4885 |
| US-20180296527-A1 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | ADH1C, ADH1A, ADH5 | SLC6A2 28/4885SLC6A4 37/4885SLC6A3 4/4885 |
| US-20210161863-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | COMT, SLC6A3, HTR3A | SLC6A2 11/4885SLC6A4 25/4885SLC6A3 2/4885 |
| US-20180256542-A1 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | COMT, SLC6A3, HTR3A | SLC6A2 11/4885SLC6A4 25/4885SLC6A3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.